BioCentury | Oct 19, 2019
Product Development

How GSK has rebuilt its oncology pipeline from the ground up

Less than two years into GSK's cancer rebuild, Hal Barron is making measurable strides to reposition the pharma as an immunology-focused company. His turnaround boasts an expanded immuno-oncology pipeline, replete with multiple modalities, and two...
BC Innovations | Jul 11, 2019
Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
BioCentury | Mar 15, 2019
Product Development

Broadening the PARP playing field

With its latest clinical win for Lynparza, AstraZeneca is leading the field in stretching the use of PARP inhibitors beyond tumors that carry BRCA mutations. The results highlight one piece of a broader strategy companies...
BioCentury | Feb 9, 2019
Product Development

Merck KGaA's large-scale partnering

Merck KGaA's deal with GlaxoSmithKline plc to develop cancer therapy M7824 enables Merck to pursue a more ambitious development plan than it could have done by going it alone, and provides a template for how...
BC Week In Review | Feb 8, 2019
Company News

Via Merck KGaA Deal, GSK adds to growing immuno-oncology pipeline

Two months after announcing it would pay $5.1 billion for Tesaro Inc., GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has partnered with Merck KGaA (Xetra:MRK) in another deal to bolster its immuno-oncology pipeline. GSK is paying the German...
BC Extra | Feb 5, 2019
Company News

Via Merck KGaA deal, GSK adds to growing immuno-oncology pipeline

Two months after announcing it would pay $5.1 billion for Tesaro Inc., GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) has partnered with Merck KGaA (Xetra:MRK) in another deal to bolster its immuno-oncology pipeline. GSK is paying the German...
BC Week In Review | Jul 13, 2018
Clinical News

Merck KGaA reports Phase I response data for M7824 in HPV-associated cancer

Merck KGaA (Xetra:MRK) reported response data at the American Society of Clinical Oncology (ASCO) meeting in Chicago from a Phase I trial of M7824 to treat advanced or metastatic HPV-associated malignancies, including cervical, anal and...
BC Week In Review | Jul 13, 2018
Clinical News

Merck KGaA reports Phase I response data for M7824 in NSCLC

Merck KGaA (Xetra:MRK) reported response data at the American Society of Clinical Oncology (ASCO) meeting in Chicago from a cohort of patients with advanced non-small cell lung cancer in a Phase I trial of M7824....
BioCentury | Jun 16, 2018
Product Development

NSCLC disrupted

This year’s ASCO made clear that PD-1 inhibitors have supplanted chemotherapy as standard of care in first-line metastatic NSCLC. The unanticipated consequence is the knock-on effects for companies with studies under way in both first-...
BioCentury | Jun 9, 2018
Product Development

POC for cytokines

A body of clinical evidence is emerging that two different approaches to immune-stimulating cytokine therapies could increase efficacy of PD-1 inhibitors in both hot and cold tumors. Oncologists who spoke to BioCentury said, taken together,...
Items per page:
1 - 10 of 12